The landscape of FGFR-TACC fusion in adult glioblastoma: From bench to bedside
Open Access
- 15 April 2025
- journal article
- review article
- Published by Elsevier in Mutation Research - Reviews in Mutation Research
- Vol. 795, 108536
Abstract
No abstract availableKeywords
Funding Information
- Tianjin Municipal Natural Science Foundation (21JCYBJC00930)
- National Natural Science Foundation of China (82203484)
This publication has 101 references indexed in Scilit:
- Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype GlioblastomasCurrent Neurology and Neuroscience Reports, 2023
- DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survivalActa Neuropathologica, 2022
- Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2Angewandte Chemie International Edition, 2021
- Targeting the HSP90–CDC37–kinase chaperone cycle: A promising therapeutic strategy for cancerMedicinal Research Reviews, 2021
- Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent GlioblastomaThe Oncologist, 2020
- cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”Acta Neuropathologica, 2018
- FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytomaActa Neuropathologica, 2018
- Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathwayActa Neuropathologica, 2016
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumoursThe Journal of Pathology, 2013